Polyamine Inhibition with DFMO: Shifting the Paradigm in Neuroblastoma Therapy
Neuroblastoma is a common childhood malignancy, and high-risk presentations, including an MYCN amplified status, continue to result in poor survival. Difluoromethylornithine (DFMO) is a new and well-tolerated treatment for high-risk[...]
Panobinostat Synergizes with Chemotherapeutic Agents and Improves Efficacy of Standard-of-Care Chemotherapy Combinations in Ewing Sarcoma Cells
There has been little improvement in Ewing sarcoma survival rates over the past several decades and new therapeutic options are desperately needed. Histone deacetylases (HDACs) are known to play a[...]
DFMO inhibition of neuroblastoma tumorigenesis
Most high-risk neuroblastoma patients who relapse succumb to disease despite the existing therapy. We recently reported increased event-free and overall survival in neuroblastoma patients receiving difluoromethylornithine (DFMO) during maintenance therapy.[...]
Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial
A total of 186 eligible patients were enrolled with 144 evaluable for safety and 124 evaluable for response. The average number of days from biopsy to initiation of the MTB‑recommended[...]
Maintenance DFMO Increases Survival in High Risk Neuroblastoma
High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This[...]
Molecular-Guided Therapy for the Treatment of Relapsed/Refractory Neuroblastoma: Results from Beat Childhood Cancer Research Consortium Trial MGT009
Molecular-Guided Therapy for the Treatment of Relapsed/Refractory Neuroblastoma: Results from Beat Childhood Cancer Research Consortium Trial MGT009 Jaqueline Kraveka, William Ferguson, Genevieve Bergendahl, Thomas Clinch, Elizabeth Lorenzi, Donald A. Berry, Javier[...]
A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma
Eslin D, Zage PE, Bergendahl G, Lewis E, Roberts W, Kraveka J, Mitchell D, Isakoff MS, Rawwas J, Wada RK, Fluchel M, Brown VI, Ginn K, Higgins T, BeeravallyNagulapally A,[...]
Tolerability and Safety of Eflornithine (DFMO) in High-Risk Neuroblastoma (HRNB) Patients Treated with DFMO Maintenance Therapy
Tolerability and Safety of Eflornithine (DFMO) in High-Risk Neuroblastoma (HRNB) Patients Treated with DFMO Maintenance Therapy Jaqueline Kraveka, William Ferguson, Genevieve Bergendahl, Thomas Clinch, Elizabeth Lorenzi, Donald A. Berry, Javier Oesterheld,[...]
Subset Analysis of the role of MYCN in DFMO treated patients
Subset Analysis of the role of MYCN in DFMO treated patients Giselle Saulner Sholler, William Ferguson, Genevieve Bergendahl, Thomas Clinch, Elizabeth Lorenzi, Donald A. Berry, Javier Oesterheld, Valerie I. Brown, Don[...]
Sensitivity Analyses of Event Free and Overall Survival in High-Risk Neuroblastoma Patients Receiving Eflornithine (DFMO) Maintenance Treatment with Matched External Controls
Sensitivity Analyses of Event Free and Overall Survival in High-Risk Neuroblastoma Patients Receiving Eflornithine (DFMO) Maintenance Treatment with Matched External Controls, Giselle Saulner Sholler, William Ferguson, Genevieve Bergendahl, Thomas Clinch, Elizabeth[...]